EUCTR2018-000139-28-DE进行中（未招募）1 期
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with histologically or cytologically confirmed metastatic NSCLC (Cohort A) or non-squamous NSCLC (Cohort B), who have not received prior systemic treatment for their metastatic disease.
- •a. No known sensitizing EGFR or ALK mutations
- •b. Solitary metastases must be biopsied to confirm the diagnosis metastasis from NSCLC
- •2. PD-L1 tumor expression of greater than or equal to 50% (Cohort A) or below 50% (Cohort B). PD-L1 tumour expression should be confirmed prior to randomization using the DAKO 22C3 assay, using local/central services.
- •3. A male participant able to father a child must agree to use contraception starting with the screening visit and through 120 days after last dose of pembrolizumab or 180 days after last dose of chemotherapy.
- •4. A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies:
- •a. Not a woman of childbearing potential (WOCBP)
- •b. A WOCBP who agrees to follow contraceptive guidance starting with the screening visit and through 120 days after last dose of pembrolizumab or 180 days after last dose of chemotherapy.
- •5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial in accordance with ICH-GCP and local legislation prior to admission to the trial.
- •6. Be ³18 years of age on day of signing informed consent.
- •7. Have measurable disease per RECIST 1.1 as assessed by local site investigator/radiologist. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- •8. Have provided a blood sample and archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded tissue blocks are preferred to slides.
- •Note: If archival tissue is available, it is preferred this is obtained less than or equal to 90 days prior to randomization. If using unstained cut slides, newly cut slides should be used for the testing, within 14 days from the date slides are cut.
- •9. Have an ECOG performance status of 0 to 1.
- •10. Have adequate organ function. Specimens must be collected within 10 days prior to the start of trial treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1. A WOCBP who has a positive urine pregnancy test (e.g., within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)
- •3. Has received prior systemic anti-cancer therapy in the first line setting for the participant's metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to diagnosis of metastatic disease).
- •Note: Participants must have recovered from all AEs due to previous therapies to =Grade 1 or baseline. Participants with =Grade 2 neuropathy may be eligible.
- •Note: If participant received major surgery, they must have recovered adequately from the adverse events and/or complications from the intervention prior to starting trial treatment.
- •4. Has received prior radiotherapy to the lung >30 Gy within 6 months of start of trial treatment. Participants must have recovered from all radiation-related adverse events, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
- •5. Has received a live vaccine within 30 days prior to the first dose of trial treatment. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
- •6. Is currently participating in or has participated in a trial of an investigational agent (e.g. small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug in the neoadjuvant or adjuvant setting) or has used an investigational device within 6 months prior to the first dose of trial treatment.
- •Note: Participants who have entered the follow-up phase of an investigational trial may participate as long as it has been 6 months after the last dose of the previous investigational agent.
- •7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial treatment.
- •8. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years.
- •Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ that have undergone potentially curative therapy are not excluded.
- •9. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of trial treatment.
- •10. Has severe hypersensitivity (=Grade 3) to IO102, pembrolizumab, carboplatin, pemetrexed and/or any of its excipients.
- •11. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying ag
研究者
相似试验
已完成
不适用
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer10027476Lung CancerNon-Small Cell Lung CancerNL-OMON46066IO Biotech Aps16
进行中（未招募）
1 期
A study investigating the use of IO102 in combination with pembrolizumab, with or without chemotherapy, for patients with metastatic non-small cell lung cancer.EUCTR2018-000139-28-ESIO Biotech Aps108
进行中（未招募）
1 期
A study investigating the use of IO102 in combination with pembrolizumab, with or without chemotherapy, for patients with metastatic non-small cell lung cancer.Metastatic Non-Small Cell Lung CancerEUCTR2018-000139-28-NLIO Biotech Aps108
进行中（未招募）
1 期
A study investigating the use of IO102 in combination with pembrolizumab, with or without chemotherapy, for patients with metastatic non-small cell lung cancer.EUCTR2018-000139-28-GBIO Biotech Aps108
进行中（未招募）
1 期
Clinical study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiencyEUCTR2011-004154-25-ITBiotest AG20